Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
155.04
-0.43 (-0.28%)
Official Closing Price
Updated: 7:00 PM EST, Nov 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Johnson & Johnson
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
3 Dividend Stocks For Passive Income
January 17, 2023
I'm aiming to grow my passive income this year through adding these safe value stocks to my portfolio that have strong dividend yields.
Via
MarketBeat
Topics
Economy
Exposures
Economy
These Steelmakers Deserve A Place On Your 2023 Watch List
December 23, 2022
Steel stocks including Nucor and Steel Dynamics are bringing holiday cheer to investors as they have potential to benefit from infrastructure spending in 2023.
Via
MarketBeat
Johnson & Johnson Completes Acquisition of Abiomed
December 22, 2022
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022
December 14, 2022
From
Johnson & Johnson
Via
Business Wire
Financial Resources Federal Credit Union Taps Scienaptic's Platform to Power its Credit Decisions With AI
January 11, 2023
NEW YORK - Jan. 11, 2023 - PRLog -- Leading global AI-powered credit decision platform provider, Scienaptic AI, announced today that Financial Resources Federal Credit Union has chosen to implement its...
Via
PRLog
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
December 13, 2022
From
Johnson & Johnson
Via
Business Wire
Two Blue Chip Health Companies The Institutions Are Buying
December 12, 2022
Johnson & Johnson and Abbott Laboratories are two Dividend Kings the analysts are buying, one stock is ready to rebound and the other to lead the market.
Via
MarketBeat
MarketBeat: Week in Review 12/05 – 12/09
December 10, 2022
The markets continue to have a lot to digest before there can be a Santa Claus raly. Here are some of the top stories our analysts were covering this week.
Via
MarketBeat
Topics
Economy
Electric Vehicles
Supply Chain
Exposures
Electric Vehicles
Interest Rates
Supply Chain
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
December 09, 2022
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months.
Via
MarketBeat
Johnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 07, 2022
From
Johnson & Johnson
Via
Business Wire
Baby Needs Market to Eyewitness Massive Growth by 2027 : Johnson & Johnson, Kimberly Clark, Procter & Gamble
December 07, 2022
Stay up-to-date with Baby Needs Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board
November 30, 2022
From
Johnson & Johnson
Via
Business Wire
Four Healthcare Stocks To Watch This Week
November 16, 2022
Healthcare has long been a wise investment, as the industry consistently grows yearly. Some analysts believe that trend will continue.
Via
MarketBeat
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
November 16, 2022
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Healthcare and Medical Leaders Gather to Shape the Future of Global Health
November 11, 2022
Via
ACN Newswire
Topics
Economy
Exposures
Economy
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
November 10, 2022
Learn more about Organicell Regenerative Medicine, Inc.from this latest report.
Via
TheNewswire.com
Exposures
COVID-19
Product Safety
Spotlight on Healthcare Collaboration and Innovation at Asia Summit on Global Health and HK International Medical and Healthcare Fair
November 10, 2022
Via
ACN Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
November 08, 2022
From
Brodsky & Smith LLC
Via
GlobeNewswire
Blue Chip Stocks and Dividend Yields
November 07, 2022
How to invest in blue chip stocks, exactly? The short answer: carefully, just like with any other investment. Investing in blue-chip stocks depends on your preferences, risk tolerance, portfolio...
Via
MarketBeat
Johnson & Johnson (NYSE: JNJ) Set to Acquire Abiomed (NASDAQ: ABMD) for $16.6 Billion or $380 per Share Plus CVR
November 01, 2022
Abiomed, Inc. (NASDAQ: ABMD) is engaged as a medical technology company, which is focused on providing support and resources to
Via
Spotlight Growth
Exposures
Product Safety
Johnson & Johnson to Acquire Abiomed
November 01, 2022
From
Johnson & Johnson
Via
Business Wire
Inaugural International Healthcare Week promotes Hong Kong as leading healthcare hub
October 31, 2022
Via
ACN Newswire
Exposures
COVID-19
Eli Lilly Dividend: Does Eli Lilly Pay Dividends?
October 27, 2022
Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stock than a simple “yes” answer. The Eli Lilly dividend is safe enough but it may not be right for all...
Via
MarketBeat
MarketBeat: Week in Review 10/17-10/21
October 22, 2022
Stocks are staging a rally to end the week. But economic data next week may bring more volatility. Here are some of the most popular articles from this week
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Merck Nears Breakout Point After October Surprise Good News
October 19, 2022
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
October 19, 2022
JNJ stock is seen as a defensive play which has typically done well in bear markets. But there is one issue that makes longer-term forecasts uncertain
Via
MarketBeat
Topics
Economy
Exposures
Economy
Johnson & Johnson Reports Q3 2022 Results
October 18, 2022
From
Johnson & Johnson
Via
Business Wire
Is Pfizer Stock Still Worth Buying After the Pandemic?
October 12, 2022
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations.
Via
MarketBeat
Exposures
COVID-19
Janssen celebrates World Mental Health Day to raise awareness on the importance of timely diagnosis and treatment
October 10, 2022
Janssen, Pharmaceutical Companies of Johnson & Johnson, is immensely proud of the many ground-breaking mental health innovations has pioneered over the course of its 60+ year legacy in the field.
Via
Newswire.com
Johnson & Johnson to Participate in the Credit Suisse 31st Annual Healthcare Conference
October 03, 2022
From
Johnson & Johnson
Via
Business Wire
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.